The purpose of this study is to compare the usual treatment alone (FOLFOX +/– Nivolumab) to the usual treatment with the addition of a third chemotherapy drug called irinotecan (mFOLFIRINOX +/– Nivolumab). Learn more about the A022102 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
A022102
A Randomized Phase III Trial of mFOLFIRINOX +/– Nivolumab vs. FOLFOX +/– Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
